May 26, 2020 -- Merck and Ridgeback Biotherapeutics announced that they have entered a collaboration to develop EIDD-2801, an orally available antiviral candidate in early clinical development for treatment of patients with COVID-19.
EIDD-2801 is an investigational, orally available ribonucleotide analog that inhibits the replication of RNA viruses, including SARS-CoV-2. In animal studies, EIDD-2801 has been shown to improve lung function and reduce viral load. The antiviral candidate was invented at Drug Innovations at Emory (DRIVE), a not-for-profit biotechnology company wholly owned by Emory University.
Under the agreement, Merck will gain exclusive worldwide rights to develop and commercialize EIDD-2801 and related molecules. Ridgeback Bio will receive an undisclosed upfront payment with the potential for specified milestone payments. Merck will be responsible for clinical development, regulatory filings, and manufacturing.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
